Alimera Sciences (ALIM)
(Delayed Data from NSDQ)
$5.60 USD
+0.04 (0.72%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $5.60 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth B Momentum B VGM
Brokerage Reports
Alimera Sciences, Inc. [ALIM]
Reports for Purchase
Showing records 1 - 20 ( 97 total )
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
2023 Financial Results Reported; Reiterate Buy; Raising PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
U.K. NICE Final Guidance Recommends Access to ILUVIEN; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
NEW DAY Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
YUTIQ Acquired for $82.5M Cash Plus Royalties; Lowering PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Full-Year 2022 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Marketing Authorization Application for ILUVIEN Submitted in Switzerland; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Solid Product Sales Growth in 2Q22; Reiterate Buy; Raising PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Financial Results Reported; Reiterate Buy; Lowering PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
2021 Financial Results Reported; Reiterate Buy; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Two-Year Real-World Data Show Reduction in Treatment Burden; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Financial Results Reported; Reiterate Buy; Reducing PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Financial Results; Top Line In Line, Bottom Line Miss; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
ILUVIEN Greater China and Western Pacific Licensing Deal; Raising PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y